Skip to content
type1.science
Phase 2RecruitingNCT06474598

MTX228 adaptive phase 2 study in T1D

What this study tests

Adaptive phase 2 study of MTX228 in type 1 diabetes; included as a watch-list adjunct/drug-development record.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2026-04-13.

Source dates appear in the references where available; this record has no dated citation metadata.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Adults 18–65 with T1D for at least a year, HbA1c 6–10%, residual fasting or random C-peptide at least 100 pmol/L, BMI at most 35 kg/m² and eGFR above 45 mL/min/1.73 m². CGM use and data sharing are required; see registry for diagnosis and exclusion details. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted yet.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: Canada. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • Change in AUC C-peptide
  • Dose selection for phase IIb study

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

  1. [1]